Sucampo Pharma (SCMP) Tops Q2 EPS by 6c; Boosts FY15 EPS Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Sucampo (SCMP) PT Raised to $25 at Maxim Group
August 5, 2015 3:48 PM EDTMaxim Group analyst Jason Kolbert reiterated a Buy rating on Sucampo Pharmaceuticals (NASDAQ: SCMP) and boosted his price target to $25.00 (from $20.00), saying Amitiza continues to grow and now they look at the end game.
Kolbert commented, "Sucampo delivered another solid quarter... More
Sucampo Pharmaceuticals (SCMP) PT Raised to $27 at Guggenheim on 'Beat and Raise'
August 5, 2015 11:14 AM EDTGuggenheim analyst Louise Chen reiterated a Buy rating and raised her price target on Sucampo Pharmaceuticals (NASDAQ: SCMP) to $27.00 (from $23.00) following 'beat and raise; Q3.
Chen commented, "Post SCMP's 2Q15 beat-and-raise quarter, we have increased our PT to $27 from $23, driven by... More
